To enhance anti-tumor antibody binding by NK cells, we expressed a novel recombinant FcγR consisting of the extracellular region of the high affinity FcγR CD64 and the transmembrane and intracellular regions of CD16A. This evidence concerns the gene FCGR1A and neoplasm.